The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term follow-up of psilocybin-facilitated smoking cessation
Open accessAbstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psychedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin-assisted psychotherapy (PAT) also appears to be safe and potentially efficacious for substance use disorders, based on early trials for nicotine and alcohol use disorders [14,15], with little evidence of harmful use in the community [16].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Psilocybin occasioned mystical experiences are defined by acute feelings of unity, sacredness, a noetic quality, positive mood, transcendence of space/time, and ineffability (6), and have previously shown a significant association with successful psilocybinfacilitated smoking cessation outcomes at 6-month followup (11…”
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“psilocybin-facilitated treatment of alcohol dependence (24), the present findings indicate that 5-HT2AR agonists may hold therapeutic potential in treating a variety of”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“Consistent with previously published data (4), no participants reported an increase in bothersome visual”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citation
Research works printed but not linked: 1
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco
Cited by
Sorted by citations
Items 401–500 of 694
The Therapeutic Effects of Classic Psychedelics in Alcohol Use Disorder
Pagni, B. A., Wong, J. M., & Bogenschutz, M. P. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00581-z · Cited by 6
Argento, E., Goldenberg, S. M., Deering, K., Lavalley, J., Braschel, M. C., Bingham, B., & Shannon, K. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100044 · Cited by 6
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Bhatt, S. R., Armstrong, M., Parker, T., Maviglia, M. A., Kass, R., Leeman, L. M., Romo, P., & Ziedonis, D. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905753 · Cited by 8
Psychedelics and Desistance From Crime: Lessons From the Concord Prison Experiment
Neitzke‐Spruill, L. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221136233 · Cited by 7
Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics
Kruger, D. J., Barron, J., Herberholz, M., & Boehnke, K. F. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2228784 · Cited by 6
Abrams, S. K., Rabinovitch, B. S., Zafar, R. R., Aziz, A. S., Cherup, N. P., McMillan, D. W., Nielson, J. L., & Lewis, E. C. (2023) · Neurotrauma Reports · doi:10.1089/neur.2023.0022 · Cited by 6
Weintraub, M. J., Jeffrey, J. K., Grob, C. S., Ichinose, M. C., Bergman, R. L., Cooper, Z. D., & Miklowitz, D. J. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0018 · Cited by 5
Szerman, N., Parro-Torres, C., Vega, P., Basurte-Villamor, I., & Ruíz-Veguilla, M. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1427561 · Cited by 8
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders
Valdez, T., Patel, V., Senesombath, N., Hatahet-Donovan, Z., & Hornick, M. G. (2024) · Pharmaceuticals · doi:10.3390/ph17111484 · Cited by 5
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective
Marazziti, D., Weiss, F., Gurrieri, R., Russomanno, G., Gambini, M., Magnesa, A., Coccoglioniti, A., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2445016 · Cited by 5
Psychedelics for Psychiatric Disorders: Promise, Not Panacea
Earleywine, M., & Herrmann, Z. M. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220810-01 · Cited by 6
Barber, M., Gardner, J., & Carter, A. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100202 · Cited by 5
Chapter 1. Theoretical Models of Psychodynamic Psychotherapy
Fonagy, P., Hepworth, M., & Campbell, C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg01 · Cited by 5
Kiilerich, K. F., Lorenz, J., Scharff, M. B., Speth, N., Brandt, T. G., Czurylo, J., Xiong, M., Jessen, N. S., Casado-Sainz, A., Shalgunov, V., et al. (2023) · doi:10.31219/osf.io/gy6m9 · Cited by 5
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4242829/v1 · Cited by 5
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2025) · eLife · doi:10.7554/elife.104006 · Cited by 5
Kettner, H., Roseman, L., Gazzaley, A., Carhart-Harris, R., & Pasquini, L. (2024) · Research Square · doi:10.21203/rs.3.rs-3977169/v1 · Cited by 5
Abramsky-Sze, S., Marseille, E. A., Matzopoulos, R., Morlock, R., & Lerer, L. B. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1508811 · Cited by 4
Richard, J., Scott, J., Nayak, S. M., Sepeda, N. D., Lowe, M. X., Jackson, H., & Garcia‐Romeu, A. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01489-z · Cited by 4
Self-citationEkoh, F., Rerrie, S., Angud, J., & Mirabelli, E. (2025) · Psychoactives · doi:10.3390/psychoactives4040039 · Cited by 4
In naturalistic psychedelic use, group use is common and acceptable
Byrne, K., Lindsay, S., Baker, N. J., Schmutz, C., & Lewis, B. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00261 · Cited by 5
Jones, J. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1096298 · Cited by 4
Exploring serotonergic psychedelics as a treatment for personality disorders
Carrithers, B. M., Roberts, D. E., Weiss, B., King, J. D., Carhart-Harris, R. L., Gordon, A. R., Pagni, B. A., Moreau, M., Ross, S., & Zeifman, R. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110413 · Cited by 4
Pharmacies as potential providers of harm reduction services: A preliminary online survey
James, E., Robertshaw, T. L., Westwell, A. D., & Smith, A. P. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767441 · Cited by 4
Psilocybin and magic mushrooms: Patterns of abuse and consequences of recreational misuse
Brito-da-Costa, A. M., da Silva, D. D., Madureira-Carvalho, Á., & Dinis‐Oliveira, R. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_130-1 · Cited by 4
Psychedelics for Alzheimer's Disease Palliative Care
McManus, K. R., Patrick, R. E., Striepe, M. I., Drury, M. J., Ozonsi, R., Forester, B. P., & Weinberg, M. S. (2022) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2022.06.001 · Cited by 4
Chapter 5. Transference-Focused Psychotherapy for Levels of Personality Pathology Severity
Clarkin, J. F., Caligor, E., & Sowislo, J. F. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg05 · Cited by 4
Chapter 4. Theory and Practice of Mentalization-Based Treatment
BATEMAN, A. W., Choi-Kain, L. W., & Unruh, B. T. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg04 · Cited by 8
“To learn healing knowledge”: Philosophy, psychedelic studies and transformation
Pittaway, D. A. (2018) · South African Journal of Philosophy · doi:10.1080/02580136.2018.1532186 · Cited by 4
Kraus, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.009 · Cited by 5
Serotonin and serotonin receptors in hallucinogen action
Halberstadt, A. L., & Nichols, D. E. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00043-8 · Cited by 4
Pasquini, L., Vohryzek, J., Escrichs, A., Perl, Y. S., Ponce‐Alvarez, A., Idesis, S., Girn, M., Roseman, L., Mitchell, J., Gazzaley, A. H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.06.622302 · Cited by 4
Formoso, K. A. (2023) · Consciousness Spirituality & Transpersonal Psychology · doi:10.53074/cstp.2023.63 · Cited by 3
Psychedelics for substance use disorders: are women being addressed? A scoping review
Nigri, A. W., de Arruda, I. F., Maia, C. G. F., Tófoli, L. F., & Carezzato, F. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104960 · Cited by 3
Du, X., Liu, J., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03291-8 · Cited by 3
Cognitive control as a transdiagnostic mechanism of action in psychedelic effects
Sayalı, C., Truesdale, A., Rosen, D. S., & Barrett, F. S. (2025) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-025-01362-5 · Cited by 3
The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors
Cameron, L. P., Jaster, A. M., Ramos, R., & Ullman, E. Z. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100093 · Cited by 4
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia‐Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117010 · Cited by 4
Self-citationChaplains in Psychedelic Assisted Therapy: Rationale and Competencies
Lewis, S. P., Clark‐Soles, J., Mayorga, O., Sawyer, S. K., Slavet, E., Vidt, B. J., Shanti, S., Wiggins, R., Willis, K., Frey, J., et al. (2026) · Journal of Religion and Health · doi:10.1007/s10943-026-02591-9 · Cited by 4
Consciousness as a domain of extraterritoriality
Falcon, J. (2021) · Culture, theory and critique/Culture, theory & critique · doi:10.1080/14735784.2021.1908904 · Cited by 3
Chapter 2. Techniques of Psychodynamic Psychotherapy
Gabbard, G. O., & Crisp-Han, H. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg02 · Cited by 3
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch, D. E.-W., López, J. P., Dalla, C., Ċastrén, E., Erritzøe, D., Frøkjær, V. G., Lundberg, J., Preller, K. H., Fisher, P. M., & Knudsen, G. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103929 · Cited by 4
Higgins, G. A., MacMillan, C., de Lannoy, I., Tyler, C., & Slassi, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251361453 · Cited by 3
Modification of natural tryptamines for the treatment of neuropsychiatric diseases
Palfreyman, M. G., Varty, G. B., Stang, E. M., Boltaev, U., Avery, K., & Nivorozhkin, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368362 · Cited by 3
Traditional Amazonian medicine in addiction treatment: Qualitative results
O’Shaughnessy, D. M., Sarnyai, Z., Quirk, F. H., & Rodd, R. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100086 · Cited by 4
Szerman, N., Carlos, P., Pinet, C., Martínez-Raga, J., Basurte, I., & Sáiz, P. A. (2022) · Actas Españolas de Psiquiatría · Cited by 4
The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa
Foster, S. W. (2023) · Law Democracy & Development · doi:10.17159/2077-4907/2023/ldd.v27.1 · Cited by 3
Black, T. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1159843 · Cited by 3
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
Cuttler, C., Stueber, A., Simone, J. J., & Mayo, L. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2452226 · Cited by 3
Psilocybin: A brief overview for psychiatric mental health nurse practitioners
Fradkin, D. (2021) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12888 · Cited by 3
“Go Ask Alice”: The Case for Researching Schedule I Drugs
Iserson, K. V. (2018) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180118000518 · Cited by 3
Mountain-Ray, S., Simeone, C., Hadland, S. E., Finnell, D. S., Northup, R., & MacLane-Baeder, D. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1695039 · Cited by 3
Psychedelics and schizophrenia: A mystery in history
Haden, M., Woods, B., & Paschall, S. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00277 · Cited by 6
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2026) · eLife · doi:10.7554/elife.104006.3 · Cited by 9
Cirillo, M. A. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251321040 · Cited by 4
Pouyan, N., Aday, J. S., Harte, S. E., Kaplan, C. M., Williams, D. A., Glynos, N. G., Herberholz, M., Kruger, D. J., Barron, J., Mashour, G. A., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251330763 · Cited by 2
Weintraub, M. J., Miklowitz, D. J., & Jeffrey, J. K. (2025) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000853 · Cited by 2
Becoming a Psychedelic User: Reflections on Howard Becker and the (Future) Sociology of Psychedelics
Rose, J. R. (2025) · Sociology Compass · doi:10.1111/soc4.70096 · Cited by 2
Bernal, A. M. O., Raison, C. L., Lancelotta, R., Timmermann, C., Sepeda, N. D., & Davis, A. K. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2577305 · Cited by 1
Qeadan, F., McCunn, A., Tingey, B., & Thielking, P. D. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1648104 · Cited by 2
Brown, R. E., Lissemore, J. I., Shinozuka, K., Coetzee, J. P., Faerman, A., Olash, C., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120722 · Cited by 2
Moshfeghinia, R., Mostafavi, S., Jazi, K., Ghasemi, A. R., Khosravani-Nezhad, Y., Narayanan, S., Ahmadi, J., & Pasalar, M. (2026) · BMC Psychology · doi:10.1186/s40359-025-03935-y · Cited by 2
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
Dallery, J., Miller, J. L., Boissoneault, J., Harvey, L., Ives, L., Knerr, A. W., Blaes, S., Ransom, M. N., Munson, M. S., Gilligan, J. P., et al. (2026) · Journal of Eating Disorders · doi:10.1186/s40337-025-01508-3 · Cited by 3
Carlisle, N. A., Simonsson, O., MacCarthy, S., Elliott, M. N., Miller, G. H., Goldberg, S. B., Shallcross, R. A., & Hendricks, P. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-37609-5 · Cited by 4
Moral Considerations and the Experience of Ego Dissolution: Insights from Psilocybin
Karimov, A., & Rasulov, D. (2025) · Asian Journal of Ethics in Health and Medicine · doi:10.51847/ml10ckoxsw · Cited by 2
Ekins, T. G., Deng, T., & Ahmed, O. J. (2026) · Brain and Behavior · doi:10.1002/brb3.71406 · Cited by 2
The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy
Heilman, J. (2023) · Journal of Scientific Exploration · doi:10.31275/20222633 · Cited by 7
Steinberg, M. I., Rosenberg, P., & Garcia‐Romeu, A. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00395-3 · Cited by 3
Self-citationVargas-Pérez, H., Minauro‐Sanmiguel, F., Ting‐A‐Kee, R. A., Grieder, T. E., Méndez‐Díaz, M., Prospero-Garcia, O. E., & van der Kooy, D. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137597 · Cited by 3
Fletcher, P. J., Li, Z., Ji, X. D., & Lê, A. D. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173703 · Cited by 3
At the Forefront: Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse
Parker, C., & Wood, B. M. (2024) · Social Work · doi:10.1093/sw/swae019 · Cited by 4
Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study
Peck, S. K., Shao, S., Gruen, T., Yang, K. H., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022013 · Cited by 2
Psychedelic Use and Behavioral Addictions
Brasher, T. J., Rosen, D., & Spinella, M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2474244 · Cited by 2
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 3
Holborn, T., Schifano, F., Smith, E., & Deluca, P. (2025) · Psychoactives · doi:10.3390/psychoactives4030028 · Cited by 4
Case Report: Resolution of Rheumatoid Arthritis in a Patient Consuming Psilocybin Mushrooms
Lin Denise, S. (2020) · Journal of Healthcare · doi:10.36959/569/456 · Cited by 2
Johnson, S., & Black, Q. C. (2020) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00398-7 · Cited by 4
Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature
Nigam, K. B., & Pandurangi, A. K. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-00871-x · Cited by 2
Whole-brain modeling to predict optimal deep brain stimulation targeting
Fernandes, H. M., Deco, G., & Kringelbach, M. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821861-7.00011-7 · Cited by 2
Initiating Pharmacologic Treatment in Tobacco-Dependent Adults
Ellison-Barnes, A., & Galiatsatos, P. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.07.008 · Cited by 2
Youssef, F. F., Widelski, J., & Kukula-Koch, W. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18657-8.00022-0 · Cited by 2
Pharmakotherapie, Psychotherapie oder „Superplacebos“?
Gründer, G., Brand, M., Färber, L. V., Kärtner, L., Kunz, L. C., Rohrmoser, B., Scharf, D., Schmitz, C. N., Spangemacher, M., & Mertens, L. J. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00709-6 · Cited by 2
Psychedelic Experiences and the Enactive Approach
Meling, D., & Scheidegger, M. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.9 · Cited by 2
Hopper, J. W. (2020) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2020.1718968 · Cited by 2
Integrating the ineffable: a social phenomenological analysis of the psychedelic experience
Neitzke‐Spruill, L. (2025) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/dyjg-0344 · Cited by 2
Ferenstein, G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3910688 · Cited by 2
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2021) · doi:10.31234/osf.io/xqzu2 · Cited by 2
Chapter 35. Combining Medications and Psychotherapy
Mintz, D. L. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg35 · Cited by 2
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2025) · eLife · doi:10.7554/elife.104006.1 · Cited by 2
Mennenga, S. E., Hanson, T., Semple, M. G., Lifshitz, D., Flores, B., Balducci, J., Harker, S. A., Ford, A., & Lewis, C. R. (2025) · Research Square · doi:10.21203/rs.3.rs-7890051/v1 · Cited by 2
Sharchaton, A., Parsha, S., Azerrad, S. P., Dekel, Y., Rabah, N., Páleníček, T., & Kurzbaum, E. (2026) · Journal of Fungi · doi:10.3390/jof12070486 · Cited by 1
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.006 · Cited by 1
What Conceptual Metaphors Appear in Texts on Psychedelics and Medicine? Corpus-Based Cognitive Study
Bryła, M. (2022) · Respectus Philologicus · doi:10.15388/respectus.2022.42.47.115 · Cited by 1
Strika-Bruneau, L., Fauvel, B., Dupuis, D., & Benyamina, A. (2023) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2023.01.003 · Cited by 1
Chapter 21. Theories and Techniques of Group Therapy
Bhatt-Mackin, S. M., & Leszcz, M. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg21 · Cited by 1
Chapter 32. Professional Boundaries and Ethics in Psychotherapy
Gabbard, G. O., & Crisp-Han, H. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg32 · Cited by 1
Adamski, C., Vaucel, J.-A., Paradis, C., Brunet, C., Nardon, A., Courtois, A., Malard, F., Castaing, N., & Labadie, M. (2024) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2023.12.002 · Cited by 1
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Corresponding author
- Johnson, Matthew W.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 43
- Issue
- 1
- Pages
- 55-60
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC5641975
- OpenAlex
- W2506717582
- Cited by
- 696
- References
- 23
- Citations by year
- 2026: 53 · 2025: 100 · 2024: 89 · 2023: 112 · 2022: 131 · 2021: 63 · 2020: 83 · 2019: 17 · 2018: 31 · 2017: 13 · 2016: 3
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-01-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, smoking cessation, smoking abstinence, long-term follow-up, cognitive behavioral therapy, classic psychedelics, addiction treatment, spiritual experience
- MeSH terms
- Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Cognitive Behavioral Therapy, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
